GlassScriptPhysician profile
Michael P Ramos
NPI 1538182779
$15,416.95
in general payments reported to CMS, 2019-2025
43 companies · $2,216 in 2025
The $2,216 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,726 · 2020: $1,314 · 2021: $2,391 · 2022: $2,484 · 2023: $2,610 · 2024: $2,676 · 2025: $2,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,439 · Education: $63.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,438.68 |
| Education | $63.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,056.20 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $2,379.29 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,491.86 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| United Therapeutics Corporation | $974.24 | 2019-2025 | Tyvaso, Tyvaso |
| Insmed, INC. | $862.37 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $820.95 | 2020-2025 | Uptravi, Opsumit, Opsynvi |
| Grifols USA, LLC | $690.14 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $578.26 | 2020-2025 | Glassia |
| Harmony Biosciences LLC | $441.99 | 2022-2025 | Wakix |
| Genzyme Corporation | $437.47 | 2021-2025 | |
| Genentech USA, INC. | $410.28 | 2019-2023 | Xolair |
| Baxter Healthcare | $365.34 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Amgen INC. | $276.66 | 2023-2025 | Tezspire, Tavneos |
| Axsome Therapeutics, INC. | $268.81 | 2022-2025 | Sunosi |
| Electromed, INC. | $262.90 | 2019-2025 | Smartvest |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $225.77 | 2019-2024 | Yupelri |
| Philips North America LLC | $209.97 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $190.84 | 2019-2022 | |
| 3b Medical, INC. | $134.47 | 2024 | Luna |
| Pulmonx Corporation | $133.98 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Sunovion Pharmaceuticals INC. | $114.76 | 2019-2021 | |
| Advanced Respiratory, INC | $108.20 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $105.21 | 2022-2025 | Dupixent |
| Inspire Medical Systems, INC. | $97.66 | 2023-2025 | Inspire |
| Circassia INC. | $85.36 | 2019-2020 | |
| Resmed Corp | $73.51 | 2020-2025 | |
| Abbvie INC. | $72.83 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $65.91 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $54.75 | 2021-2024 | Acthar |
| Avadel Cns Pharmaceuticals, LLC | $54.51 | 2024 | Lumryz |
| Merck Sharp & Dohme LLC | $51.48 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $47.70 | 2024 | Purified Cortrophin Gel |
| Inogen, INC. | $42.71 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Olympus America INC. | $39.78 | 2022-2024 | Single-Use Flexible Video Bronchoscope |
| Viatris Specialty LLC | $35.71 | 2025 | Yupelri |
| Alexion Pharmaceuticals, INC. | $30.07 | 2021-2023 | Ultomiris |
| Zoll Respicardia, INC. | $29.87 | 2023-2024 | Remede System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.35 | 2020 | |
| Phadia US INC. | $18.86 | 2022 | |
| Pfizer INC. | $17.78 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $13.69 | 2023 | Eliquis |
| Allergan, INC. | $13.00 | 2020 | |
| Merit Medical Systems INC | $12.46 | 2024 | Aspira |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.